Evidence map›Paper›PMID 35451668›Full record

ArticleClinical and experimental medicine2023

Clinicopathological characteristics, survival outcome and prognostic factors of very young gastric cancer.

Niuniu Zhong, Yi Yu, Jun Chen, Yuanyuan Shao, Zhiqiang Peng, Junhe Li

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Global burden of young-onset gastric cancer: a systematic trend analysis of the global burden of disease study 2019.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Article
  4. Article
  5. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Niuniu Zhong *Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang, 330006, Jiangxi, China.
Yi Yu *Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang, 330006, Jiangxi, China.
Jun Chen *Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang, 330006, Jiangxi, China.
Yuanyuan ShaoDepartment of General Practice, The Second Affiliated Hospital, Nanchang University, Nanchang, 330008, Jiangxi, China.
Zhiqiang PengDepartment of Oncology, Jiangxi Tumor Hospital, Nanchang University, Nanchang, 330029, Jiangxi, China.
Junhe LiDepartment of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang, 330006, Jiangxi, China. ljh1231211@163.com.ORCID http://orcid.org/0000-0002-3066-8269
Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To explore the clinicopathological characteristics, survival outcomes, and prognosis of very young gastric cancer (GC). From January 1, 2011 to January 1, 2021, GC patients under 30 years old treated in three tertiary hospitals were enrolled. Clinicopathological characteristics were summarized, prognostic factors and survival outcomes including overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) were retrospectively analyzed. One hundred patients were finally included, with a median age of 23 years.73 (73.0%) were female. Most patients had initial symptoms of abdominal pain (66.0%). The most common tumor locations were gastric antrum (38.0%) and gastric body (37.0%). The main histological types were diffuse (81.0%) and poorly differentiated (91.0%). Most patients presented with stage III-IV disease (82.0%) at diagnosis and the common sites of metastasis were ovary (39.5%) and peritoneum (27.6%). The mOS of the whole group was 23.3 months (95% CI 17.2-29.4). Moreover, the mOS of patients at stage I-II was not reached. The mOS of patients at stage III and stage IV was 40.6 months (95% CI 10.2-70.9) and 10.3 months (95% CI 8.9-11.6), respectively. The mDFS of stage I-III patients was 28.5 months (95% CI 14.7-42.3), and the mPFS of the metastatic patients was 4.5 months (95% CI 4.0-5.0). TNM stage (P = 0.005) and radical surgery (P = 0.001) were independent prognostic factors of overall survival. The very young GC were predominantly female, diffuse type, and advanced diagnosis. TNM stage and radical surgery were independent prognosis factors for overall survival.

Indexed as

Stomach NeoplasmsAdultFemaleGastrectomyHumansMaleNeoplasm StagingPrognosisRetrospective StudiesYoung AdultClinicopathological characteristicsGastric cancerPrognosis factorsVery young

Identifiers

PMID35451668
OpenAlexW4224295702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.